SCHEMBL25070271

SCHEMBL25070271

CCOC(=O)c1cnn2c(N(C)C(=O)OC(C)(C)C)cc(-c3cn(C(=O)OC(C)(C)C)c4c(C)cc(C)cc34)cc12

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 1/20 0.33
▸ ALDH1A1 P00352 4/20 0.32
▸ SMN1; SMN2 Q16637 2/20 0.32
▸ GAA P10253 2/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ LMNA P02545 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32
▸ TP53 P04637 1/20 0.31
▸ POLB P06746 1/20 0.31
▸ L3MBTL1 Q9Y468 1/20 0.31
▸ KDM4E B2RXH2 4/20 0.30
▸ HPGD P15428 4/20 0.30
▸ HSD17B10 Q99714 3/20 0.30
▸ RAB9A P51151 2/20 0.30
▸ NPC1 O15118 1/20 0.30
▸ HIF1A Q16665 1/20 0.30
▸ CASP1 P29466 2/20 0.30
▸ KLK7 P49862 1/20 0.30
▸ TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25070273 0.91 BRD4 (0.31) —
SCHEMBL25070274 0.90 TLR8 (0.32) —
SCHEMBL20689532 0.85 KDM4E (0.41) GPR119ALDH1A1SMN1; SMN2GAAMEN1
SCHEMBL25069973 0.83 CYP1A2 (0.43) ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10
SCHEMBL20689529 0.78 KDM4E (0.34) ALDH1A1GAAMEN1LMNAKMT2A
SCHEMBL21285404 0.78 MAPT (0.39) ALDH1A1GAAMEN1KMT2ATP53
SCHEMBL20689531 0.77 TYK2 (0.36) ALDH1A1L3MBTL1KDM4EHPGDHSD17B10
SCHEMBL21246137 0.75 POLB (0.40) ALDH1A1SMN1; SMN2GAAMEN1LMNA
SCHEMBL25069986 0.71 SMN1; SMN2 (0.42) ALDH1A1SMN1; SMN2MEN1LMNAKMT2A
SCHEMBL20696812 0.70 KDM4E (0.43) ALDH1A1SMN1; SMN2GAAPOLBL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230056447-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-02-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230056447-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 GPR119 2576/4885ALDH1A1 4827/4885SMN1; SMN2 1145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback